N@N

Agennix AG to Present at Lazard Capital Markets 6th Annual Healthcare Conference

_{//health-fitness.news-articles.net/content/2009/ .. al-markets-6th-annual-healthcare-conference.html}
^{Published in Health and Fitness on Friday, November 13th 2009 at 2:47 GMT by Market Wire}  

MARTINSRIED/MUNICH, GERMANY and PRINCETON, NJ and HOUSTON, TX--(Marketwire - November 13, 2009) - Agennix AG (FRANKFURT: AGX) today announced that the Company will give a corporate presentation at the upcoming Lazard Capital Markets 6th Annual Healthcare Conference. The presentation will be on Wednesday, November 18, at 2:15 p.m. ET at the St. Regis Hotel in New York City.

The presentation will be webcast live and will be accessible through the Agennix Web site at [ www.agennix.com ]. A replay will also be available via the Web site.

About Agennix

Agennix AG is a publicly traded biopharmaceutical company focused on developing novel anti-cancer therapies. The Company was formed by the combination of GPC Biotech AG and Agennix Incorporated. The Company's most advanced program is talactoferrin, an oral targeted therapy that is in Phase 3 clinical trials in non-small cell lung cancer. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase 1 testing; the oral platinum-based compound satraplatin; and a topical gel form of talactoferrin for wound healing. Agennix is a transatlantic company with sites in Munich, Germany; Princeton, New Jersey and Houston, Texas. For additional information, please visit the Agennix Web site at [ www.agennix.com ].

This press release contains forward-looking statements, which express the current beliefs and expectations of the management of Agennix AG. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date on which they are made and Agennix undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.